Alican Gulsevin

Dr. Alican Gulsevin

Vanderbilt University
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2022 in Structure
Verified
Journal Article
Closed access
EMEli Fritz McDonald
Eli Fritz McDonald
TJTaylor Jones
Taylor Jones
LPLars Plate
Lars Plate
JMJens Meiler
Jens Meiler
Alican GulsevinAlican Gulsevin
Alican Gulsevin

1 June 2019 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
Alican GulsevinAlican Gulsevin
Alican Gulsevin
Roger PapkeRoger Papke
Roger Papke
CSClare Stokes
Clare Stokes
SGSumanta Garai
Sumanta Garai
GTGanesh A. Thakur
Ganesh A. Thakur
NHNicole Horenstein
Nicole Horenstein
Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of ligand-gated ion channels. Typically, channel activation follows the binding of agonists to the orthosteric binding sites of the receptor. α7 nAChRs have a very low probability of channel activation, which can be reversed by the binding of α7 selective positive allosteric modulators (PAMs) to putative sites within the transmembrane domains. Although typical PAMs, like PNU-120596, require coapplication of an orthosteric agonist to produce large channel activations, some, like GAT107 and B-973B [(S)-3-(3,4-difluorophenyl)-N-(1-(6-(4-(pyridin-2-yl)piperazin-1-yl)pyrazin-2-yl)ethyl)propanamide], are characterized as allosteric activating PAMs, which also bind to an allosteric activation (AA) site in the extracellular domain and activate the α7 ion channel by themselves. We had previously characterized N,N-diethyl-N′-phenylpiperazine analogs with various functions. In this work, we docked members of this family to a homology model of the α7 receptor extracellular domain. The compound 1,1-diethyl-4(naphthalene-2-yl)piperazin-1-ium (2NDEP) a weak partial agonist, showed particularly favorable docking and binding energies at the putative AA site of the receptor. We hypothesized that 2NDEP could couple with PAMs through the AA site. This hypothesis was tested with the α7 mutant C190A, which is not activated by orthosteric agonists but is effectively activated by GAT107. The results showed that 2NDEP acts as an allosteric agonist of α7C190A when coapplied with the PAM PNU-120596. Also, the allosteric activity was nearly abolished upon coapplication with the AA site–selective antagonist 2,3,5,6MP-TQS (cis-trans-4-(2,3,5,6-tetramethylphenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide), consistent with AA site involvement. Overall, our findings show a novel mode of agonism through an allosteric site in the extracellular domain of α7 nAChR.

1 January 2019 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
MQMarta Quadri
Marta Quadri
SGSumanta Garai
Sumanta Garai
GTGanesh A. Thakur
Ganesh A. Thakur
CSClare Stokes
Clare Stokes
Alican GulsevinAlican Gulsevin
Alican Gulsevin
Roger PapkeRoger Papke
Roger Papke
B-973 is an efficacious type II positive allosteric modulator (PAM) of α7 nicotinic acetylcholine receptors that, like 4BP-TQS and its active isomer GAT107, is able to produce direct allosteric activation in addition to potentiation of orthosteric agonist activity, which identifies it as an ago-PAM. We compare the properties of B-973B, the active enantiomer of B-973, to those of GAT107 in regard to separation of allosteric potentiation and activation. Both ago-PAMs are able to strongly activate mutants of α7 that are insensitive to standard orthosteric agonists like acetylcholine. Likewise, the activity of both ago-PAMs is largely eliminated by the M254L mutation in the putative transmembrane PAM binding site. Allosteric activation by B-973B appears more protracted than that produced by GAT107, and B-973B responses are relatively insensitive to the noncompetitive antagonist mecamylamine compared to GAT107 responses. Similar differences are also seen in the single-channel currents. The two agents generate unique profiles of full-conductance and subconductance states, with B-973B producing protracted bursts even in the presence of mecamylamine. Modeling and docking studies suggest that the molecular basis for these effects depends on specific interactions in both the extracellular and transmembrane domains of the receptor.

Verified
Journal Article
Open access
PDF file
Alican GulsevinAlican Gulsevin
Alican Gulsevin
AGAndrew Glazer
Andrew Glazer
TSTiffany Shields
Tiffany Shields
BKBrett M. Kroncke
Brett M. Kroncke
DRDan M. Roden
Dan M. Roden
JMJens Meiler
Jens Meiler
The cardiac sodium ion channel (NaV1.5) is a protein with four domains (DI-DIV), each with six transmembrane segments. Its opening and subsequent inactivation results in the brief rapid influx of Na+ ions resulting in the depolarization of cardiomyocytes. The neurotoxin veratridine (VTD) inhibits NaV1.5 inactivation resulting in longer channel opening times, and potentially fatal action potential prolongation. VTD is predicted to bind at the channel pore, but alternative binding sites have not been ruled out. To determine the binding site of VTD on NaV1.5, we perform docking calculations and high-throughput electrophysiology experiments in the present study. The docking calculations identified two distinct binding regions. The first site was in the pore, close to the binding site of NaV1.4 and NaV1.5 blocking drugs in experimental structures. The second site was at the “mouth” of the pore at the cytosolic side, partly solvent-exposed. Mutations at this site (L409, E417, and I1466) had large effects on VTD binding, while residues deeper in the pore had no effect, consistent with VTD binding at the mouth site. Overall, our results suggest a VTD binding site close to the cytoplasmic mouth of the channel pore. Binding at this alternative site might indicate an allosteric inactivation mechanism for VTD at NaV1.5.

21 January 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
HAHugo R. Arias
Hugo R. Arias
DRDeborah Rudin
Deborah Rudin
DHDustin J. Hines
Dustin J. Hines
ACApril Contreras
April Contreras
Alican GulsevinAlican Gulsevin
Alican Gulsevin
Abdeslam CHAGRAOUIAbdeslam CHAGRAOUI
Abdeslam CHAGRAOUI

14 September 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MQMarta Quadri
Marta Quadri
CSClare Stokes
Clare Stokes
Alican GulsevinAlican Gulsevin
Alican Gulsevin
AFAshley C. J. Felts
Ashley C. J. Felts
KAKhalil A. Abboud
Khalil A. Abboud
NHNicole Horenstein
Nicole Horenstein